相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study
Hsien-Yi Chiu et al.
ACTA DERMATO-VENEREOLOGICA (2018)
Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
A. Egeberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Psoriasis in Taiwan: From epidemiology to new treatments
Hsien-Yi Chiu et al.
DERMATOLOGICA SINICA (2018)
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR
Kayleigh J. Mason et al.
JAMA DERMATOLOGY (2018)
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations
Sofia Ajeganova et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2017)
Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort
C. Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries
Sang Woong Youn et al.
ANNALS OF DERMATOLOGY (2016)
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
Bruce E. Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis
Hsien-Yi Chiu et al.
ACTA DERMATO-VENEREOLOGICA (2015)
Combining biologics with methotrexate in psoriasis: a systematic review
J. S. van Bezooijen et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers
Tzu-Chang Wang et al.
DERMATOLOGICA SINICA (2015)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Robert E. Kalb et al.
JAMA DERMATOLOGY (2015)
Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis
H. -Y. Chiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C
H. -Y. Chiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan
Yi-Fang Wu et al.
DERMATOLOGICA SINICA (2013)
Etanercept use for psoriasis in Taiwan: a case series study
Hsien-Yi Chiu et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2013)
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
A. B. Kimball et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
P. Rich et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
T helper type 17 in psoriasis: From basic immunology to clinical practice
Hsien-Yi Chiu et al.
DERMATOLOGICA SINICA (2012)
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
Tsen-Fang Tsai et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2011)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs
F. Cantini et al.
RHEUMATOLOGY (2008)
Relapse, rebound, and psoriasis adverse events: An advisory group report
W Carey et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy
KB Gordon et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2006)
Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
AB Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
分享论文
